Abstract
The G-protein-coupled receptor 55 (GPR55) was identified in 1999. It was proposed as a novel member of the endocannabinoid system due to the fact that some endogenous, plant-derived and synthetic cannabinoid ligands act on GPR55. However, the complexity of the cellular downstream signaling pathways related to GPR55 activation delayed the discovery of selective GPR55 ligands. It was only a few years ago that the high throughput screening of libraries of pharmaceutical companies and governmental organizations allowed to identify selective GPR55 agonists and antagonists. Since then, several GPR55 modulator scaffolds have been reported. The relevance of GPR55 has been explored in diverse physiological and pathological processes revealing its role in inflammation, neuropathic pain, bone physiology, diabetes and cancer. Considering GPR55 as a new promising therapeutic target, there is a clear need for new selective and potent GPR55 modulators. This review will address a current structural update of GPR55 ligands.
Keywords: Agonist, Antagonist, Cannabinoid, Endocannabinoid, GPCR, GPR55, Structure.
Current Medicinal Chemistry
Title:Advances Towards The Discovery of GPR55 Ligands
Volume: 23 Issue: 20
Author(s): Paula Morales and Nadine Jagerovic
Affiliation:
- Instituto de Química Médica, Consejo Superior de Investigaciones Científicas, Calle Juan de la Cierva, 3, Madrid E-28230, Spain,Spain
Keywords: Agonist, Antagonist, Cannabinoid, Endocannabinoid, GPCR, GPR55, Structure.
Abstract: The G-protein-coupled receptor 55 (GPR55) was identified in 1999. It was proposed as a novel member of the endocannabinoid system due to the fact that some endogenous, plant-derived and synthetic cannabinoid ligands act on GPR55. However, the complexity of the cellular downstream signaling pathways related to GPR55 activation delayed the discovery of selective GPR55 ligands. It was only a few years ago that the high throughput screening of libraries of pharmaceutical companies and governmental organizations allowed to identify selective GPR55 agonists and antagonists. Since then, several GPR55 modulator scaffolds have been reported. The relevance of GPR55 has been explored in diverse physiological and pathological processes revealing its role in inflammation, neuropathic pain, bone physiology, diabetes and cancer. Considering GPR55 as a new promising therapeutic target, there is a clear need for new selective and potent GPR55 modulators. This review will address a current structural update of GPR55 ligands.
Export Options
About this article
Cite this article as:
Morales Paula and Jagerovic Nadine, Advances Towards The Discovery of GPR55 Ligands, Current Medicinal Chemistry 2016; 23(20) . https://dx.doi.org/10.2174/0929867323666160425113836
DOI https://dx.doi.org/10.2174/0929867323666160425113836 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets Preeclampsia as a Multifactorial Pregnancy Disorder: Clinical Symptoms,Diagnostic Tools and Research Strategies
Current Women`s Health Reviews Current Research on Opioid Receptor Function
Current Drug Targets Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets Combined Treatment Fkt-Botulinum Toxin Type A (Btx-A) in Patients with Strumpell-Lorrain Disease
Current Pharmaceutical Design Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry A Review on Phytochemistry and Pharmacology of Medicinal as well as Poisonous Mushrooms
Mini-Reviews in Medicinal Chemistry Current and Promising Pharmacotherapies, and Novel Research Target Areas in the Treatment of Alcohol Dependence: A Review
Current Pharmaceutical Design Cytokine and Nitric Oxide Production Following Severe Envenomation
Current Drug Targets - Inflammation & Allergy Drug-Induced Hypokalaemia
Current Drug Safety Advances in the Synthesis of Calystegines and Related Products and their Biochemical Properties
Mini-Reviews in Medicinal Chemistry TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry L-Arginine Transport and Nitric Oxide Production in Kinin Receptor B1-/- Endothelial Cells.
Protein & Peptide Letters Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design The Role of Corticosteroids in Sepsis and Acute Respiratory Distress Syndrome
Current Respiratory Medicine Reviews Practical Review of Mechanical Ventilation in Adults and Children in the Operating Room and Emergency Department
Reviews on Recent Clinical Trials Calcium-Independent Membrane Damage by Venom Phospholipases A2
Protein & Peptide Letters